Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56.

Published byNatalie Kearney Modified over 10 years ago

Similar presentations

Presentation on theme: "Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56."— Presentation transcript:

1 Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

2 Baseline Characteristics of the Study Population Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

3 Angiographic and Procedural Characteristics Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

4 Characteristics of Patients With Definite or Probable ST Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

5 Kaplan-Meier analysis for the cumulative incidence of stent thrombosis (A) and for the composite of death or stent thrombosis (B) Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

6 Distribution of ST Across Quintiles Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

7 Clinical Outcome Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56

Download ppt "Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56."

Similar presentations

Baseline Characteristics According to CET Rate Marianne Zeller, et al. J Am Coll Cardiol 2007;50:1948-55.

Baseline Characteristics According to CET Rate Marianne Zeller, et al. J Am Coll Cardiol 2007;50:
Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:403-14.

Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:
Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.

Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Quartiles of complete blood count components Jeffrey L. Anderson, et al. Am J Cardiol 2007;99:169-174.

Quartiles of complete blood count components Jeffrey L. Anderson, et al. Am J Cardiol 2007;99:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Ho PM, et al. JAMA 2009;301:937-44. Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.

Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Thrombosis of Second-Generation Drug-Eluting Stents.

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Thrombosis of Second-Generation Drug-Eluting Stents.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.
Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Similar presentations

Ads by Google